Silence Therapeutics plc (SLN)

Silence Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	43.26	31.64	21.66	16.81	7.48
Revenue Growth (YoY)	36.71%	46.12%	28.82%	124.73%	2214.81%
Cost of Revenue	11.81	12.87	13.46	10.1	5.14
Gross Profit	31.45	18.78	8.19	6.71	2.34
Selling, General & Admin	26.88	26.22	25.68	27.09	19.09
Research & Development	54.15	44.99	33.73	41.66	27.59
Other Operating Expenses	-	-	-	-	-2.04
Operating Expenses	81.03	71.21	59.41	68.75	44.65
Operating Income	-49.58	-52.43	-51.22	-62.03	-42.3
Interest Expense	-	-	-	-0.01	-0.02
Interest & Investment Income	-	-	-	0.01	0.18
Currency Exchange Gain (Loss)	0.65	-2.64	1.29	-0.06	-7.06
Other Non Operating Income (Expenses)	4.47	1.8	0.28	-	-
EBT Excluding Unusual Items	-44.46	-53.27	-49.65	-62.09	-49.21
Pretax Income	-44.46	-53.27	-49.65	-62.09	-49.21
Income Tax Expense	0.85	0.96	0.69	-8.73	-4.77
Net Income	-45.31	-54.23	-50.33	-53.36	-44.44
Net Income to Common	-45.31	-54.23	-50.33	-53.36	-44.44
Shares Outstanding (Basic)	46	37	32	30	27
Shares Outstanding (Diluted)	46	37	32	30	27
Shares Change (YoY)	24.69%	15.21%	8.58%	8.78%	8.85%
EPS (Basic)	-0.98	-1.46	-1.56	-1.80	-1.63
EPS (Diluted)	-0.98	-1.46	-1.56	-1.80	-1.63
Free Cash Flow	-67.85	-49.52	-57.22	7.44	-15.41
Free Cash Flow Per Share	-1.47	-1.33	-1.78	0.25	-0.56
Gross Margin	72.70%	59.34%	37.83%	39.94%	31.34%
Operating Margin	-114.62%	-165.70%	-236.53%	-369.02%	-565.49%
Profit Margin	-104.74%	-171.37%	-232.44%	-317.44%	-594.03%
Free Cash Flow Margin	-156.85%	-156.49%	-264.22%	44.26%	-206.00%
EBITDA	-48.99	-51.81	-50.62	-61.69	-41.62
EBITDA Margin	-113.25%	-163.74%	-233.78%	-	-
D&A For EBITDA	0.59	0.62	0.6	0.34	0.68
EBIT	-49.58	-52.43	-51.22	-62.03	-42.3
EBIT Margin	-114.62%	-165.70%	-236.53%	-	-

Updated Feb 27, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q